Stock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales

Stock Track

01/14

TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.

The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with Briumvi U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including Briumvi U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.

CEO Michael Weiss highlighted Briumvi's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of Briumvi.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1195674953"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195674953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1195674953?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195674953","market":"nz","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales","media":"Stock Track","content":"<p>TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.</p><p>The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with Briumvi U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including Briumvi U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.</p><p>CEO Michael Weiss highlighted Briumvi's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of Briumvi.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-14 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.</p><p>The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with Briumvi U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including Briumvi U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.</p><p>CEO Michael Weiss highlighted Briumvi's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of Briumvi.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1195674953","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195674953","pubTimestamp":1768401283,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"个股追踪|TG Therapeutics盘中大涨17.83%，营收前景强劲，Briumvi销售","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with Briumvi U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including Briumvi U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.CEO Michael Weiss highlighted Briumvi's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of Briumvi.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}